Neurogene Inc. Total Liabilities
Neurogene Inc. (NGNE) had Total Liabilities of $27.23 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-11
- 2026-06-30: Liabilities $27.23M.
- 2026-03-31: Liabilities $25.36M.
- 2025-12-31: Liabilities $23.72M.
- 2025-09-30: Liabilities $22.29M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $27.23M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $25.36M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $23.72M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $22.29M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $24.06M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $23.51M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $25.36M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $26.71M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $24.81M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $24.57M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $36.55M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $14.35M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $14.43M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $17.10M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $10.64M 10-K · filed 2024-03-18 | $21.62M 10-K · filed 2023-03-20 |
| 2022-09-30 | $20.93M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $20.31M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $19.03M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $20.40M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $21.07M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $19.95M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $21.14M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $19.30M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $21.35M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $16.63M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $15.93M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $5.34M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $2.92M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $1.41M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $3.89M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $4.95M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $11.09M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $13.75M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $9.80M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $11.44M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $7.51M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $8.68M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $6.39M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $9.72M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $8.71M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $8.61M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $5.83M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $4.92M 10-K · filed 2017-03-09 | |
| 2015-09-30 | $4.00M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $4.05M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $5.05M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $5.28M 10-K · filed 2016-03-14 | $5.28M 10-K · filed 2015-03-16 |
| 2014-09-30 | $4.64M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $2.94M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.35M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $7.48M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |